MedImmune Expands Oncology Pipeline With Therapeutic Protein Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
Agreement with Avidia is firm's eleventh licensing deal or acquisition of validated targets for product development in the last 12 months.